AMIPAQUE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMIPAQUE is an injectable diagnostic agent manufactured by GE HealthCare, approved in 1978 as an NDA product. The drug's specific mechanism of action, pharmacologic class, and clinical indications are not disclosed in available data. It is administered via injection and represents a mature diagnostic or imaging product from the company's portfolio.
LOE Approaching
As a 46-year-old product approaching loss of exclusivity, the AMIPAQUE brand team is likely small and focused on defending market share against generic and newer competitors in a declining market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AMIPAQUE currently shows zero linked job openings, reflecting its mature, declining market position. Career growth is limited; opportunities exist primarily in defensive commercial strategies, cost optimization, and transition planning as the product approaches LOE.
Brand ManagerProduct Manager
Worked on AMIPAQUE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.